MFA
VRTX icon

Mayflower Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Mayflower Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Sell
1,681
-70
-4% -$31K 0.07% 216
2026
Q1 		$782K Buy
1,751
+343
+24% +$160K 0.09% 199
2025
Q4 		$638K Buy
1,408
+155
+12% +$66.8K 0.08% 212
2025
Q3 		$491K Sell
1,253
-160
-11% -$66.9K 0.06% 255
2025
Q2 		$629K Sell
1,413
-78
-5% -$35.9K 0.09% 204
2025
Q1 		$723K Buy
1,491
+10
+0.7% +$4.66K 0.11% 179
2024
Q4 		$596K Sell
1,481
-1
-0.1% -$464 0.09% 200
2024
Q3 		$689K Sell
1,482
-727,830
-100% -$350M 0.1% 179
2024
Q2 		$1.37M Buy
729,312
+173
+0% +$75.1K 0.22% 99
2024
Q1 		$1.23M Buy
729,139
+27
+0% +$11.4K 0.21% 110
2023
Q4 		$1.2M Sell
729,112
-23
-0% -$8.5K 0.17% 116
2023
Q3 		$1.14M Sell
729,135
-425
-0.1% -$149K 0.17% 112
2023
Q2 		$1.3M Buy
729,560
+5
+0% +$1.69K 0.17% 112
2023
Q1 		$1.24M Buy
729,555
+83
+0% +$24.9K 0.16% 114
2022
Q4 		$1.17M Sell
729,472
-186
-0% -$56.7K 0.16% 106
2022
Q3 		$1.22M Sell
729,658
-221,017
-23% -$63.6M 0.2% 95
2022
Q2 		$1.14M Buy
950,675
+32
+0% +$8.56K 0.17% 103
2022
Q1 		$1.12M Buy
950,643
+390,581
+70% +$92.7M 0.15% 105
2021
Q4 		$664K Buy
560,062
+251
+0% +$48.8K 0.09% 158
2021
Q3 		$601K Buy
559,811
+14
+0% +$2.73K 0.08% 169
2021
Q2 		$602K Sell
559,797
-60
-0% -$12.6K 0.08% 151
2021
Q1 		$618K Buy
+559,857
New +$123M 0.09% 144

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mayflower Financial Advisors's VRTX Position: Q2 2026 in Review

Mayflower Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, selling an estimated $31K and leaving 1,681 shares worth $835K. The position accounts for 0.07% of the portfolio, ranked #216.

Mayflower Financial Advisors first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.37M in Q2 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Mayflower Financial Advisors held 1,681 shares of Vertex Pharmaceuticals worth $835K as of Q2 2026.
  • Mayflower Financial Advisors sold 70 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31K.
  • Vertex Pharmaceuticals made up 0.07% of Mayflower Financial Advisors's portfolio in Q2 2026, its #216 holding.
  • Mayflower Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Mayflower Financial Advisors's Vertex Pharmaceuticals position peaked at $1.37M in Q2 2024.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mayflower Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.